<?xml version="1.0" encoding="UTF-8"?>
<specification xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ballotUrl="http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm/2024Jan" ciUrl="http://build.fhir.org/ig/HL7/ebm" defaultVersion="1.0.0-ballot" defaultWorkgroup="cds" gitUrl="https://github.com/HL7/ebm" url="http://hl7.org/fhir/uv/ebm">
<version code="current" url="http://build.fhir.org/ig/HL7/ebm"/>
<version code="1.0.0-ballot" url="https://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm/2024Jan"/>
<artifactPageExtension value="-definitions"/>
<artifactPageExtension value="-examples"/>
<artifactPageExtension value="-mappings"/>
<artifact id="Evidence/55" key="Evidence-55" name="14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"/>
<artifact id="Citation/179628" key="Citation-179628" name="14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist."/>
<artifact id="DeviceDefinition/179899" key="DeviceDefinition-179899" name="179899"/>
<artifact id="Citation/179602" key="Citation-179602" name="18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers."/>
<artifact id="Citation/179637" key="Citation-179637" name="18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal."/>
<artifact id="Citation/179631" key="Citation-179631" name="19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."/>
<artifact id="Citation/179627" key="Citation-179627" name="19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial."/>
<artifact id="Citation/179603" key="Citation-179603" name="19967827 Wonder woman was Argentine and her real name was Evita."/>
<artifact id="Citation/179626" key="Citation-179626" name="22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial."/>
<artifact id="Citation/179625" key="Citation-179625" name="22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial."/>
<artifact id="Citation/179615" key="Citation-179615" name="23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial."/>
<artifact id="Citation/179623" key="Citation-179623" name="23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer."/>
<artifact id="Citation/179629" key="Citation-179629" name="23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer."/>
<artifact id="Citation/179624" key="Citation-179624" name="24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."/>
<artifact id="Citation/179617" key="Citation-179617" name="25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the &#34;Docetaxel Era&#34;: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)."/>
<artifact id="Citation/179622" key="Citation-179622" name="26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."/>
<artifact id="Citation/179621" key="Citation-179621" name="26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial."/>
<artifact id="Citation/179630" key="Citation-179630" name="26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer."/>
<artifact id="Citation/179616" key="Citation-179616" name="26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer."/>
<artifact id="Citation/33089" key="Citation-33089" name="27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations."/>
<artifact id="Citation/179613" key="Citation-179613" name="27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."/>
<artifact id="Citation/179601" key="Citation-179601" name="29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego."/>
<artifact id="Citation/179600" key="Citation-179600" name="29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character."/>
<artifact id="Citation/179599" key="Citation-179599" name="29202628 &#34;I Kinda Feel Like Wonder Woman&#34;: An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image."/>
<artifact id="Citation/179598" key="Citation-179598" name="29357271 Using Hawkeye from the Avengers to communicate on the eye."/>
<artifact id="Citation/179597" key="Citation-179597" name="29694275 A regressive formula of perversity: Wertham and the women of comics."/>
<artifact id="Citation/179596" key="Citation-179596" name="29694302 Introduction: &#34;Suffering Sappho!&#34;: Lesbian content and queer female characters in comics."/>
<artifact id="Citation/179595" key="Citation-179595" name="30467172 Finding my inner Wonder Woman."/>
<artifact id="Group/33395" key="Group-33395" name="33395"/>
<artifact id="Citation/179594" key="Citation-179594" name="34871555 What Can Wonder Woman Teach Radiologists?"/>
<artifact id="Citation/33399" key="Citation-33399" name="35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis."/>
<artifact id="Citation/179605" key="Citation-179605" name="36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst."/>
<artifact id="Citation/179604" key="Citation-179604" name="6907780 Career guide: to change what needs changing...doesn't take Wonder Woman."/>
<artifact id="Evidence/179683" key="Evidence-179683" name="ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version"/>
<artifact id="StructureDefinition/adaptation" key="StructureDefinition-adaptation" name="Adaptation"/>
<artifact id="Citation/7636" key="Citation-7636" name="Anticoagulation for COVID-19 Combined RCTs in NEJM"/>
<artifact id="StructureDefinition/artifact-approvalDate" key="StructureDefinition-artifact-approvalDate" name="ArtifactApprovalDate"/>
<artifact id="StructureDefinition/artifact-assessment-compared" key="StructureDefinition-artifact-assessment-compared" name="ArtifactAssessmentCompared"/>
<artifact id="StructureDefinition/artifact-assessment-date-as-rating" key="StructureDefinition-artifact-assessment-date-as-rating" name="ArtifactAssessmentDateAsRating"/>
<artifact id="StructureDefinition/artifact-effectivePeriod" key="StructureDefinition-artifact-effectivePeriod" name="ArtifactEffectivePeriod"/>
<artifact id="StructureDefinition/artifact-lastReviewDate" key="StructureDefinition-artifact-lastReviewDate" name="ArtifactLastReviewDate"/>
<artifact id="Group/32139" key="Group-32139" name="Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16"/>
<artifact id="Group/179511" key="Group-179511" name="Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17"/>
<artifact id="Group/172423" key="Group-172423" name="Bariatric_Surgery_RYGB_VSG_LAGB_BPD"/>
<artifact id="StructureDefinition/baseline-measure-evidence" key="StructureDefinition-baseline-measure-evidence" name="BaselineMeasureEvidence"/>
<artifact id="Evidence/179451" key="Evidence-179451" name="BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group"/>
<artifact id="Evidence/179452" key="Evidence-179452" name="BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group"/>
<artifact id="Evidence/179458" key="Evidence-179458" name="BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group"/>
<artifact id="Evidence/179457" key="Evidence-179457" name="BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group"/>
<artifact id="StructureDefinition/book-citation" key="StructureDefinition-book-citation" name="BookCitation"/>
<artifact id="Citation/121719" key="Citation-121719" name="BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century"/>
<artifact id="StructureDefinition/book-part-citation" key="StructureDefinition-book-part-citation" name="BookPartCitation"/>
<artifact id="Citation/139859" key="Citation-139859" name="BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century"/>
<artifact id="Citation/139860" key="Citation-139860" name="BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation"/>
<artifact id="Evidence/179690" key="Evidence-179690" name="CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version"/>
<artifact id="Group/12714" key="Group-12714" name="COVID_19PneumoniaHospitalizedAdult"/>
<artifact id="ArtifactAssessment/179693" key="ArtifactAssessment-179693" name="Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"/>
<artifact id="StructureDefinition/certainty-of-evidence" key="StructureDefinition-certainty-of-evidence" name="CertaintyOfEvidence"/>
<artifact id="StructureDefinition/characteristic-description" key="StructureDefinition-characteristic-description" name="CharacteristicDescription"/>
<artifact id="StructureDefinition/characteristic-determined-by-expression" key="StructureDefinition-characteristic-determined-by-expression" name="CharacteristicDeterminedByExpression"/>
<artifact id="StructureDefinition/characteristic-determined-by-reference" key="StructureDefinition-characteristic-determined-by-reference" name="CharacteristicDeterminedByReference"/>
<artifact id="StructureDefinition/characteristic-duration-duration" key="StructureDefinition-characteristic-duration-duration" name="CharacteristicDurationDuration"/>
<artifact id="StructureDefinition/characteristic-duration-range" key="StructureDefinition-characteristic-duration-range" name="CharacteristicDurationRange"/>
<artifact id="StructureDefinition/characteristic-instances-quantity" key="StructureDefinition-characteristic-instances-quantity" name="CharacteristicInstancesQuantity"/>
<artifact id="StructureDefinition/characteristic-instances-range" key="StructureDefinition-characteristic-instances-range" name="CharacteristicInstancesRange"/>
<artifact id="StructureDefinition/characteristic-method" key="StructureDefinition-characteristic-method" name="CharacteristicMethod"/>
<artifact id="StructureDefinition/characteristic-offset" key="StructureDefinition-characteristic-offset" name="CharacteristicOffset"/>
<artifact id="StructureDefinition/characteristic-timing" key="StructureDefinition-characteristic-timing" name="CharacteristicTiming"/>
<artifact id="StructureDefinition/characteristic-value-expression" key="StructureDefinition-characteristic-value-expression" name="CharacteristicValueExpression"/>
<artifact id="StructureDefinition/characteristic-value-uri" key="StructureDefinition-characteristic-value-uri" name="CharacteristicValueUri"/>
<artifact id="Citation/58" key="Citation-58" name="Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"/>
<artifact id="Citation/7638" key="Citation-7638" name="Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19"/>
<artifact id="StructureDefinition/classification" key="StructureDefinition-classification" name="Classification"/>
<artifact id="ArtifactAssessment/179448" key="ArtifactAssessment-179448" name="Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort"/>
<artifact id="StructureDefinition/cohort-definition" key="StructureDefinition-cohort-definition" name="Cohort Definition"/>
<artifact id="Group/179902" key="Group-179902" name="CohortDefinition_At_least_2_risk_factors_for_stroke"/>
<artifact id="Group/179514" key="Group-179514" name="CohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery"/>
<artifact id="Group/179513" key="Group-179513" name="CohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery"/>
<artifact id="Group/179510" key="Group-179510" name="CohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery"/>
<artifact id="Group/179509" key="Group-179509" name="CohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery"/>
<artifact id="Group/179376" key="Group-179376" name="CohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity"/>
<artifact id="Group/179508" key="Group-179508" name="CohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans"/>
<artifact id="Group/179506" key="Group-179506" name="CohortDefinition_BMI_criteria_for_ADA_surgery_recommendation"/>
<artifact id="Group/170441" key="Group-170441" name="CohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years"/>
<artifact id="Group/170442" key="Group-170442" name="CohortDefinition_Cardiovascular_event"/>
<artifact id="Group/179901" key="Group-179901" name="CohortDefinition_Heart_failure_based_on_Phenotypes"/>
<artifact id="Group/179512" key="Group-179512" name="CohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration"/>
<artifact id="Group/173249" key="Group-173249" name="CohortDefinition_Nonfatal_myocardial_infarction"/>
<artifact id="Group/173250" key="Group-173250" name="CohortDefinition_Nonfatal_stroke"/>
<artifact id="Group/179898" key="Group-179898" name="CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter"/>
<artifact id="Group/179900" key="Group-179900" name="CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges"/>
<artifact id="Group/179507" key="Group-179507" name="CohortDefinition_Proxy_criteria_for_surgical_candidates"/>
<artifact id="Group/179375" key="Group-179375" name="CohortDefinition_Severe_obesity"/>
<artifact id="StructureDefinition/combination-method" key="StructureDefinition-combination-method" name="CombinationMethod"/>
<artifact id="StructureDefinition/combination-threshold" key="StructureDefinition-combination-threshold" name="CombinationThreshold"/>
<artifact id="StructureDefinition/comment" key="StructureDefinition-comment" name="Comment"/>
<artifact id="ArtifactAssessment/179694" key="ArtifactAssessment-179694" name="Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z"/>
<artifact id="StructureDefinition/comparative-baseline-measure-evidence" key="StructureDefinition-comparative-baseline-measure-evidence" name="ComparativeBaselineMeasureEvidence"/>
<artifact id="Evidence/179455" key="Evidence-179455" name="ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group"/>
<artifact id="Evidence/179456" key="Evidence-179456" name="ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group"/>
<artifact id="StructureDefinition/comparative-evidence" key="StructureDefinition-comparative-evidence" name="ComparativeEvidence"/>
<artifact id="Evidence/49328" key="Evidence-49328" name="ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis"/>
<artifact id="Evidence/32144" key="Evidence-32144" name="ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)"/>
<artifact id="Evidence/104157" key="Evidence-104157" name="ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104098" key="Evidence-104098" name="ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study"/>
<artifact id="Evidence/104155" key="Evidence-104155" name="ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104121" key="Evidence-104121" name="ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104156" key="Evidence-104156" name="ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/47740" key="Evidence-47740" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014"/>
<artifact id="Evidence/47768" key="Evidence-47768" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015"/>
<artifact id="Evidence/47759" key="Evidence-47759" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016"/>
<artifact id="Evidence/47748" key="Evidence-47748" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015"/>
<artifact id="Evidence/47760" key="Evidence-47760" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008"/>
<artifact id="Evidence/47749" key="Evidence-47749" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014"/>
<artifact id="Evidence/47751" key="Evidence-47751" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013"/>
<artifact id="Evidence/47762" key="Evidence-47762" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015"/>
<artifact id="Evidence/47752" key="Evidence-47752" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013"/>
<artifact id="Evidence/47665" key="Evidence-47665" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial"/>
<artifact id="Evidence/47695" key="Evidence-47695" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial"/>
<artifact id="Evidence/47738" key="Evidence-47738" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014"/>
<artifact id="Evidence/47758" key="Evidence-47758" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial"/>
<artifact id="Evidence/47771" key="Evidence-47771" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial"/>
<artifact id="Evidence/47766" key="Evidence-47766" name="ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014"/>
<artifact id="Evidence/33244" key="Evidence-33244" name="ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis"/>
<artifact id="StructureDefinition/comparative-evidence-report" key="StructureDefinition-comparative-evidence-report" name="ComparativeEvidenceReport"/>
<artifact id="Composition/178426" key="Composition-178426" name="ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)"/>
<artifact id="StructureDefinition/comparative-evidence-report-subject" key="StructureDefinition-comparative-evidence-report-subject" name="ComparativeEvidenceReportSubject"/>
<artifact id="Group/179633" key="Group-179633" name="ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort"/>
<artifact id="StructureDefinition/comparative-participant-flow" key="StructureDefinition-comparative-participant-flow" name="ComparativeParticipantFlow"/>
<artifact id="Evidence/179635" key="Evidence-179635" name="ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial"/>
<artifact id="StructureDefinition/comparator-definition" key="StructureDefinition-comparator-definition" name="ComparatorDefinition"/>
<artifact id="Group/172424" key="Group-172424" name="ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD"/>
<artifact id="Group/179785" key="Group-179785" name="ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis"/>
<artifact id="StructureDefinition/comparator-group" key="StructureDefinition-comparator-group" name="ComparatorGroup"/>
<artifact id="Group/172939" key="Group-172939" name="ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort"/>
<artifact id="Group/172460" key="Group-172460" name="ComparatorGroup_Obese_patients_18_years_old_without_bariatric_surgery"/>
<artifact id="StructureDefinition/comparator-only-evidence" key="StructureDefinition-comparator-only-evidence" name="ComparatorOnlyEvidence"/>
<artifact id="Evidence/104385" key="Evidence-104385" name="ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104384" key="Evidence-104384" name="ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis"/>
<artifact id="Evidence/104397" key="Evidence-104397" name="ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study"/>
<artifact id="Evidence/104395" key="Evidence-104395" name="ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104396" key="Evidence-104396" name="ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104394" key="Evidence-104394" name="ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="StructureDefinition/comparison" key="StructureDefinition-comparison" name="Comparison"/>
<artifact id="ArtifactAssessment/179700" key="ArtifactAssessment-179700" name="Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="ArtifactAssessment/171898" key="ArtifactAssessment-171898" name="Composite Rating of FOI 153881 for Project FOI 112280"/>
<artifact id="StructureDefinition/composite-rating" key="StructureDefinition-composite-rating" name="CompositeRating"/>
<artifact id="Organization/118079" key="Organization-118079" name="Computable_Publishing_LLC"/>
<artifact id="Evidence/7637" key="Evidence-7637" name="Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19"/>
<artifact id="StructureDefinition/data-dictionary" key="StructureDefinition-data-dictionary" name="DataDictionary"/>
<artifact id="CodeSystem/181451" key="CodeSystem-181451" name="DataDictionary: Measuring the Rate of Scientific Knowledge Transfer"/>
<artifact id="CodeSystem/179650" key="CodeSystem-179650" name="DataDictionary: phs003190"/>
<artifact id="StructureDefinition/database-citation" key="StructureDefinition-database-citation" name="DatabaseCitation"/>
<artifact id="Citation/29812" key="Citation-29812" name="DatabaseCitation: Citation for FEvIR Platform"/>
<artifact id="StructureDefinition/database-entry-citation" key="StructureDefinition-database-entry-citation" name="DatabaseEntryCitation"/>
<artifact id="Citation/179558" key="Citation-179558" name="DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)"/>
<artifact id="StructureDefinition/dataset-citation" key="StructureDefinition-dataset-citation" name="DatasetCitation"/>
<artifact id="Citation/179559" key="Citation-179559" name="DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes"/>
<artifact id="StructureDefinition/date-as-rating" key="StructureDefinition-date-as-rating" name="DateAsRating"/>
<artifact id="ArtifactAssessment/181452" key="ArtifactAssessment-155969" name="DateOfFirstPublication Classification of FOI 153881 by Rachel Couban"/>
<artifact id="Citation/153881" key="Citation-153881" name="Delany-Moretlwe 2022 clinical trial"/>
<artifact id="ValueSet/179430" key="ValueSet-179430" name="EBMImplementationGuideProfile Value Set"/>
<artifact id="Group/179897" key="Group-179897" name="EGFR_45_59"/>
<artifact id="StructureDefinition/endpoint-analysis-plan" key="StructureDefinition-endpoint-analysis-plan" name="EndpointAnalysisPlan"/>
<artifact id="CodeSystem/179423" key="CodeSystem-179423" name="Evidence Based Medicine on FHIR Implementation Guide Code System"/>
<artifact id="ValueSet/evidence-variable-role-subtype" key="ValueSet-evidence-variable-role-subtype" name="Evidence Variable Role Subtype Value Set"/>
<artifact id="StructureDefinition/evidence-list" key="StructureDefinition-evidence-list" name="EvidenceList"/>
<artifact id="List/179800" key="List-179800" name="EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)"/>
<artifact id="List/179470" key="List-179470" name="EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis"/>
<artifact id="StructureDefinition/evidence-map" key="StructureDefinition-evidence-map" name="EvidenceMap"/>
<artifact id="Composition/104213" key="Composition-104213" name="EvidenceMap: Bariatric Surgery Summary of Findings Example for GIN 2022"/>
<artifact id="StructureDefinition/evidence-r6" key="StructureDefinition-evidence-r6" name="EvidenceR6"/>
<artifact id="StructureDefinition/evidence-report" key="StructureDefinition-evidence-report" name="EvidenceReport"/>
<artifact id="ValueSet/179431" key="ValueSet-179431" name="EvidenceReportSectionCode Value Set"/>
<artifact id="StructureDefinition/evidence-report-subject" key="StructureDefinition-evidence-report-subject" name="EvidenceReportSubject"/>
<artifact id="Group/179562" key="Group-179562" name="EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery"/>
<artifact id="StructureDefinition/evidence-synthesis-evidence" key="StructureDefinition-evidence-synthesis-evidence" name="EvidenceSynthesisEvidence"/>
<artifact id="StructureDefinition/evidence-variable-category-value-reference" key="StructureDefinition-evidence-variable-category-value-reference" name="EvidenceVariableCategoryValueReference"/>
<artifact id="StructureDefinition/evidence-variable-definition" key="StructureDefinition-evidence-variable-definition" name="EvidenceVariableDefinition"/>
<artifact id="ValueSet/179424" key="ValueSet-179424" name="EvidenceVariableRoleSubtype Value Set"/>
<artifact id="Evidence/179691" key="Evidence-179691" name="Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version"/>
<artifact id="StructureDefinition/exposure-definition" key="StructureDefinition-exposure-definition" name="ExposureDefinition"/>
<artifact id="Group/179786" key="Group-179786" name="ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin"/>
<artifact id="StructureDefinition/exposure-group" key="StructureDefinition-exposure-group" name="ExposureGroup"/>
<artifact id="Group/172934" key="Group-172934" name="ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort"/>
<artifact deprecated="true" id="StructureDefinition/exposure-variable" key="StructureDefinition-exposure-variable" name="ExposureVariable"/>
<artifact id="EvidenceVariable/179449" key="EvidenceVariable-179449" name="ExposureVariable: Age (as continuous variable)"/>
<artifact id="EvidenceVariable/179450" key="EvidenceVariable-179450" name="ExposureVariable: Body Mass Index (as continuous variable)"/>
<artifact id="EvidenceVariable/179662" key="EvidenceVariable-179662" name="ExposureVariable: pht013093.v1.p1 Age at diagnosis"/>
<artifact id="EvidenceVariable/179661" key="EvidenceVariable-179661" name="ExposureVariable: pht013093.v1.p1 RACE"/>
<artifact id="EvidenceVariable/179658" key="EvidenceVariable-179658" name="ExposureVariable: pht013093.v1.p1 SEX"/>
<artifact id="EvidenceVariable/179649" key="EvidenceVariable-179649" name="ExposureVariable: pht013093.v1.p1 SUBJECT_ID"/>
<artifact id="EvidenceVariable/179680" key="EvidenceVariable-179680" name="ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE"/>
<artifact id="EvidenceVariable/179678" key="EvidenceVariable-179678" name="ExposureVariable: pht013094.v1.p1 BODY_SITE"/>
<artifact id="EvidenceVariable/179682" key="EvidenceVariable-179682" name="ExposureVariable: pht013094.v1.p1 IS_TUMOR"/>
<artifact id="EvidenceVariable/179677" key="EvidenceVariable-179677" name="ExposureVariable: pht013094.v1.p1 SAMPLE_ID"/>
<artifact id="EvidenceVariable/179679" key="EvidenceVariable-179679" name="ExposureVariable: pht013094.v1.p1 SAMPLE_USE"/>
<artifact id="EvidenceVariable/179681" key="EvidenceVariable-179681" name="ExposureVariable: pht013094.v1.p1 Source_Type"/>
<artifact id="StructureDefinition/group-assignment" key="StructureDefinition-group-assignment" name="GroupAssignment"/>
<artifact id="EvidenceVariable/172427" key="EvidenceVariable-172427" name="GroupAssignment: Bariatric Surgery vs. no bariatric surgery"/>
<artifact id="EvidenceVariable/172479" key="EvidenceVariable-172479" name="GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment"/>
<artifact id="EvidenceVariable/172481" key="EvidenceVariable-172481" name="GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone"/>
<artifact id="EvidenceVariable/172478" key="EvidenceVariable-172478" name="GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment"/>
<artifact id="EvidenceVariable/179784" key="EvidenceVariable-179784" name="GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis"/>
<artifact id="EvidenceVariable/179689" key="EvidenceVariable-179689" name="GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo"/>
<artifact id="StructureDefinition/group-r6" key="StructureDefinition-group-r6" name="GroupR6"/>
<artifact id="StructureDefinition/guideline" key="StructureDefinition-guideline" name="Guideline"/>
<artifact id="Composition/179465" key="Composition-179465" name="Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes"/>
<artifact id="ActivityDefinition/213" key="ActivityDefinition-213" name="IV remdesivir 200 mg then 100 mg/day for 9 days"/>
<artifact id="EvidenceVariable/33245" key="EvidenceVariable-33245" name="InterventionDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)"/>
<artifact id="EvidenceVariable/33394" key="EvidenceVariable-33394" name="InterventionDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)"/>
<artifact id="StructureDefinition/intervention-only-evidence" key="StructureDefinition-intervention-only-evidence" name="InterventionOnlyEvidence"/>
<artifact id="Evidence/104398" key="Evidence-104398" name="InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104400" key="Evidence-104400" name="InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104401" key="Evidence-104401" name="InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="Evidence/104402" key="Evidence-104402" name="InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study"/>
<artifact id="EvidenceVariable/159673" key="EvidenceVariable-159673" name="Investigator"/>
<artifact id="EvidenceVariable/156673" key="EvidenceVariable-156673" name="Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA"/>
<artifact id="ArtifactAssessment/179698" key="ArtifactAssessment-179698" name="Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="StructureDefinition/journal-article-citation" key="StructureDefinition-journal-article-citation" name="JournalArticleCitation"/>
<artifact id="Citation/32137" key="Citation-32137" name="JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes"/>
<artifact id="Citation/104116" key="Citation-104116" name="JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort"/>
<artifact deprecated="true" id="Citation/33090" key="Citation-33090" name="JournalArticleCitation: Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations"/>
<artifact id="ArtifactAssessment/179469" key="ArtifactAssessment-179469" name="Justification for Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="ArtifactAssessment/179515" key="ArtifactAssessment-179515" name="Justification for Recommendation: ADA Obesity Management Recommendation 8.17"/>
<artifact id="Composition/181448" key="Composition-181448" name="M11 Report Template Instructions"/>
<artifact id="StructureDefinition/m11-report" key="StructureDefinition-m11-report" name="M11Report"/>
<artifact id="StructureDefinition/metaanalysis-eligibility-criteria" key="StructureDefinition-metaanalysis-eligibility-criteria" name="MetaanalysisEligibilityCriteria"/>
<artifact id="Group/175766" key="Group-175766" name="MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis"/>
<artifact id="StructureDefinition/metaanalysis-outcome-definition" key="StructureDefinition-metaanalysis-outcome-definition" name="MetaanalysisOutcomeDefinition"/>
<artifact id="Group/175765" key="Group-175765" name="MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up"/>
<artifact id="StructureDefinition/metaanalysis-study-group" key="StructureDefinition-metaanalysis-study-group" name="MetaanalysisStudyGroup"/>
<artifact id="Group/179799" key="Group-179799" name="MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs"/>
<artifact id="EvidenceVariable/12719" key="EvidenceVariable-12719" name="Mortality at 14 days"/>
<artifact id="StructureDefinition/net-effect-contribution" key="StructureDefinition-net-effect-contribution" name="NetEffectContribution"/>
<artifact id="Evidence/179591" key="Evidence-179591" name="NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022"/>
<artifact id="Evidence/179586" key="Evidence-179586" name="NetEffectContribution: All-cause mortality for Example for GIN 2022"/>
<artifact id="Evidence/179589" key="Evidence-179589" name="NetEffectContribution: New onset depression for Example for GIN 2022"/>
<artifact id="Evidence/179587" key="Evidence-179587" name="NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022"/>
<artifact id="Evidence/179588" key="Evidence-179588" name="NetEffectContribution: Remission of diabetes for Example for GIN 2022"/>
<artifact id="Evidence/179590" key="Evidence-179590" name="NetEffectContribution: Treatment with opioids for Example for GIN 2022"/>
<artifact id="StructureDefinition/net-effect-contribution-list" key="StructureDefinition-net-effect-contribution-list" name="NetEffectContributionList"/>
<artifact id="List/179585" key="List-179585" name="NetEffectContributionList: Bariatric Surgery Example for GIN 2022"/>
<artifact id="StructureDefinition/net-effect-contributions" key="StructureDefinition-net-effect-contributions" name="NetEffectContributions"/>
<artifact id="Group/179584" key="Group-179584" name="NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022"/>
<artifact id="StructureDefinition/net-effect-estimate" key="StructureDefinition-net-effect-estimate" name="NetEffectEstimate"/>
<artifact id="Evidence/179583" key="Evidence-179583" name="NetEffectEstimate: Bariatric Surgery Example for GIN 2022"/>
<artifact id="StructureDefinition/non-comparative-evidence" key="StructureDefinition-non-comparative-evidence" name="NonComparativeEvidence"/>
<artifact id="EvidenceVariable/7753" key="EvidenceVariable-7753" name="Organ support-free days"/>
<artifact id="ArtifactAssessment/104064" key="ArtifactAssessment-104064" name="Outcome Importance Rating 100 of All-cause mortality"/>
<artifact id="ArtifactAssessment/104192" key="ArtifactAssessment-104192" name="Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke"/>
<artifact id="ArtifactAssessment/104194" key="ArtifactAssessment-104194" name="Outcome Importance Rating 5 of New onset depression"/>
<artifact id="ArtifactAssessment/104193" key="ArtifactAssessment-104193" name="Outcome Importance Rating 5 of Remission of diabetes"/>
<artifact id="ArtifactAssessment/104195" key="ArtifactAssessment-104195" name="Outcome Importance Rating 5 of Treatment with opioids"/>
<artifact id="ArtifactAssessment/104196" key="ArtifactAssessment-104196" name="Outcome Importance Rating 8 of Additional GI surgical procedure"/>
<artifact id="StructureDefinition/outcome-definition" key="StructureDefinition-outcome-definition" name="OutcomeDefinition"/>
<artifact id="Group/172480" key="Group-172480" name="OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control"/>
<artifact id="Group/173252" key="Group-173252" name="OutcomeDefinition_Diabetes_in_remission"/>
<artifact id="Group/172484" key="Group-172484" name="OutcomeDefinition_HbA1c_at_12_months"/>
<artifact id="Group/172477" key="Group-172477" name="OutcomeDefinition_HbA1c_at_24_months"/>
<artifact id="Group/173245" key="Group-173245" name="OutcomeDefinition_HbA1c_at_36_months"/>
<artifact id="Group/172476" key="Group-172476" name="OutcomeDefinition_HbA1c_at_60_months"/>
<artifact id="Group/175762" key="Group-175762" name="OutcomeDefinition_HbA1c_at_6_months"/>
<artifact id="Group/173251" key="Group-173251" name="OutcomeDefinition_New_onset_depression"/>
<artifact id="Group/173248" key="Group-173248" name="OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke"/>
<artifact id="StructureDefinition/outcome-importance" key="StructureDefinition-outcome-importance" name="OutcomeImportance"/>
<artifact id="StructureDefinition/outcome-list" key="StructureDefinition-outcome-list" name="OutcomeList"/>
<artifact id="List/179579" key="List-179579" name="OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery"/>
<artifact deprecated="true" id="StructureDefinition/outcome-measure-evidence" key="StructureDefinition-outcome-measure-evidence" name="OutcomeMeasureEvidence"/>
<artifact deprecated="true" id="StructureDefinition/outcome-variable" key="StructureDefinition-outcome-variable" name="OutcomeVariable"/>
<artifact id="EvidenceVariable/32143" key="EvidenceVariable-32143" name="OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years"/>
<artifact id="EvidenceVariable/173243" key="EvidenceVariable-173243" name="OutcomeVariable: HbA1c at 12 months"/>
<artifact id="EvidenceVariable/173246" key="EvidenceVariable-173246" name="OutcomeVariable: HbA1c at 24 months"/>
<artifact id="EvidenceVariable/173244" key="EvidenceVariable-173244" name="OutcomeVariable: HbA1c at 36 months"/>
<artifact id="EvidenceVariable/175763" key="EvidenceVariable-175763" name="OutcomeVariable: HbA1c at 6 months"/>
<artifact id="EvidenceVariable/173247" key="EvidenceVariable-173247" name="OutcomeVariable: HbA1c at 60 months"/>
<artifact id="EvidenceVariable/46025" key="EvidenceVariable-46025" name="OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up"/>
<artifact id="EvidenceVariable/104118" key="EvidenceVariable-104118" name="OutcomeVariable: New onset depression"/>
<artifact id="EvidenceVariable/104097" key="EvidenceVariable-104097" name="OutcomeVariable: Nonfatal myocardial infarction or stroke"/>
<artifact id="EvidenceVariable/104117" key="EvidenceVariable-104117" name="OutcomeVariable: Remission of diabetes"/>
<artifact id="EvidenceVariable/104120" key="EvidenceVariable-104120" name="OutcomeVariable_Additional_GI_surgical_procedure"/>
<artifact id="EvidenceVariable/49217" key="EvidenceVariable-49217" name="OutcomeVariable_All_cause_mortality"/>
<artifact id="EvidenceVariable/104119" key="EvidenceVariable-104119" name="OutcomeVariable_Treatment_with_opioids"/>
<artifact id="StructureDefinition/participant-flow-measure" key="StructureDefinition-participant-flow-measure" name="Participant Flow Measure"/>
<artifact id="StructureDefinition/participant-flow" key="StructureDefinition-participant-flow" name="ParticipantFlow"/>
<artifact id="Evidence/179460" key="Evidence-179460" name="ParticipantFlow: 2018 Norwegian Cohort Excluded from Analysis"/>
<artifact id="Evidence/179462" key="Evidence-179462" name="ParticipantFlow: 2018 Norwegian Cohort Included in Analysis"/>
<artifact id="Evidence/179464" key="Evidence-179464" name="ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis"/>
<artifact id="Evidence/179463" key="Evidence-179463" name="ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis"/>
<artifact id="EvidenceVariable/179636" key="EvidenceVariable-179636" name="ParticipantFlowMeasure: Dropout due to stopping intervention"/>
<artifact id="EvidenceVariable/179459" key="EvidenceVariable-179459" name="ParticipantFlowMeasure: Exclusion from analysis"/>
<artifact id="EvidenceVariable/179461" key="EvidenceVariable-179461" name="ParticipantFlowMeasure: Inclusion in analysis"/>
<artifact id="Group/7750" key="Group-7750" name="Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill"/>
<artifact id="Group/7749" key="Group-7749" name="Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill"/>
<artifact id="EvidenceVariable/12718" key="EvidenceVariable-12718" name="Placebo"/>
<artifact id="PlanDefinition/179468" key="PlanDefinition-179468" name="PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="PlanDefinition/179554" key="PlanDefinition-179554" name="PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17"/>
<artifact id="StructureDefinition/preprint-citation" key="StructureDefinition-preprint-citation" name="PreprintCitation"/>
<artifact id="Citation/5296" key="Citation-5296" name="PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint"/>
<artifact id="StructureDefinition/rating" key="StructureDefinition-rating" name="Rating"/>
<artifact id="StructureDefinition/recommendation" key="StructureDefinition-recommendation" name="Recommendation"/>
<artifact id="ValueSet/recommendation-justification-classifier" key="ValueSet-recommendation-justification-classifier" name="Recommendation Justification Classifier Codes Value Set"/>
<artifact id="CodeSystem/27834" key="CodeSystem-27834" name="Recommendation Justification Code System"/>
<artifact id="Composition/179466" key="Composition-179466" name="Recommendation: ADA Obesity Management Recommendation 8.16"/>
<artifact id="Composition/179699" key="Composition-179699" name="Recommendation: ADA Obesity Management Recommendation 8.16-adapted"/>
<artifact id="Composition/179467" key="Composition-179467" name="Recommendation: ADA Obesity Management Recommendation 8.17"/>
<artifact id="StructureDefinition/recommendation-action" key="StructureDefinition-recommendation-action" name="RecommendationAction"/>
<artifact id="StructureDefinition/recommendation-eligibility-criteria" key="StructureDefinition-recommendation-eligibility-criteria" name="RecommendationEligibilityCriteria"/>
<artifact id="StructureDefinition/recommendation-justification" key="StructureDefinition-recommendation-justification" name="RecommendationJustification"/>
<artifact id="StructureDefinition/recommendation-plan" key="StructureDefinition-recommendation-plan" name="RecommendationPlan"/>
<artifact id="EvidenceVariable/12717" key="EvidenceVariable-12717" name="Remdesivir"/>
<artifact id="Group/179783" key="Group-179783" name="Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days"/>
<artifact id="ValueSet/181524" key="ValueSet-risk-of-bias-type" name="Risk Of Bias Type Value Set"/>
<artifact id="ArtifactAssessment/179692" key="ArtifactAssessment-179692" name="Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19"/>
<artifact id="StructureDefinition/risk-of-bias" key="StructureDefinition-risk-of-bias" name="RiskOfBias"/>
<artifact id="CodeSystem/181513" key="CodeSystem-181513" name="Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide"/>
<artifact id="StructureDefinition/search-results" key="StructureDefinition-search-results" name="SearchResults"/>
<artifact id="Library/179606" key="Library-179606" name="SearchResults: PubMed search for Wonder Woman"/>
<artifact id="StructureDefinition/search-strategy" key="StructureDefinition-search-strategy" name="SearchStrategy"/>
<artifact id="Group/179592" key="Group-179592" name="SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review"/>
<artifact id="Group/179593" key="Group-179593" name="SearchStrategy_PubMed_search_for_Wonder_Woman"/>
<artifact id="Group/178427" key="Group-178427" name="Severely_Obese_Adults_2018_Norwegian_Cohort"/>
<artifact id="StructureDefinition/single-study-evidence" key="StructureDefinition-single-study-evidence" name="SingleStudyEvidence"/>
<artifact id="StructureDefinition/soa-plandefinition" key="StructureDefinition-soa-plandefinition" name="SoaPlanDefinition"/>
<artifact id="PlanDefinition/181450" key="PlanDefinition-181450" name="SoaPlanDefinition: Follow-up assessment 3 months after study start"/>
<artifact id="StructureDefinition/software-citation" key="StructureDefinition-software-citation" name="SoftwareCitation"/>
<artifact id="Citation/179560" key="Citation-179560" name="SoftwareCitation: Computable PublishingÂ®: ClinicalTrials.gov-to-FEvIR Converter"/>
<artifact id="StructureDefinition/statistic-model-applied" key="StructureDefinition-statistic-model-applied" name="StatisticModelApplied"/>
<artifact id="StructureDefinition/statistic-model-expression" key="StructureDefinition-statistic-model-expression" name="StatisticModelExpression"/>
<artifact id="StructureDefinition/statistic-model-include-if" key="StructureDefinition-statistic-model-include-if" name="StatisticModelIncludeIf"/>
<artifact id="StructureDefinition/statistic-model-intended" key="StructureDefinition-statistic-model-intended" name="StatisticModelIntended"/>
<artifact id="StructureDefinition/statistic-model-value-codeableconcept" key="StructureDefinition-statistic-model-value-codeableconcept" name="StatisticModelValueCodeableConcept"/>
<artifact id="StructureDefinition/statistic-model-value-quantity" key="StructureDefinition-statistic-model-value-quantity" name="StatisticModelValueQuantity"/>
<artifact id="StructureDefinition/statistic-model-value-range" key="StructureDefinition-statistic-model-value-range" name="StatisticModelValueRange"/>
<artifact id="Citation/33400" key="Citation-33400" name="StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488"/>
<artifact id="StructureDefinition/study-eligibility-criteria" key="StructureDefinition-study-eligibility-criteria" name="StudyEligibilityCriteria"/>
<artifact id="Group/170443" key="Group-170443" name="StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study"/>
<artifact id="Group/172461" key="Group-172461" name="StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial"/>
<artifact id="Group/171819" key="Group-171819" name="StudyEligibilityCriteria_Obese_patients_18_years_old"/>
<artifact id="StructureDefinition/study-group" key="StructureDefinition-study-group" name="StudyGroup"/>
<artifact id="Group/32145" key="Group-32145" name="StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group"/>
<artifact id="Group/46117" key="Group-46117" name="StudyGroup_DIBASY_Trial_Enrollment_Group"/>
<artifact id="StructureDefinition/summary-of-findings" key="StructureDefinition-summary-of-findings" name="SummaryOfFindings"/>
<artifact id="Composition/104215" key="Composition-104215" name="SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022"/>
<artifact id="StructureDefinition/summary-of-net-effect" key="StructureDefinition-summary-of-net-effect" name="SummaryOfNetEffect"/>
<artifact id="Composition/104383" key="Composition-104383" name="SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022"/>
<artifact id="StructureDefinition/systematic-review-eligibility-criteria" key="StructureDefinition-systematic-review-eligibility-criteria" name="SystematicReviewEligibilityCriteria"/>
<artifact id="Group/179619" key="Group-179619" name="SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer"/>
<artifact id="StructureDefinition/systematic-review-excluded-studies" key="StructureDefinition-systematic-review-excluded-studies" name="SystematicReviewExcludedStudies"/>
<artifact id="Library/179632" key="Library-179632" name="SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - Brian S. Alper"/>
<artifact id="StructureDefinition/systematic-review-included-studies" key="StructureDefinition-systematic-review-included-studies" name="SystematicReviewIncludedStudies"/>
<artifact id="Library/179618" key="Library-179618" name="SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
<artifact id="EvidenceVariable/7751" key="EvidenceVariable-7751" name="Therapeutic-dose anticoagulation with heparin"/>
<artifact id="Group/33398" key="Group-33398" name="Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis"/>
<artifact id="StructureDefinition/variable-definition" key="StructureDefinition-variable-definition" name="VariableDefinition"/>
<artifact id="StructureDefinition/variable-definition-comparator-category" key="StructureDefinition-variable-definition-comparator-category" name="VariableDefinitionComparatorCategory"/>
<artifact id="StructureDefinition/variable-definition-role-subtype" key="StructureDefinition-variable-definition-role-subtype" name="VariableDefinitionRoleSubtype"/>
<artifact id="StructureDefinition/variable-definition-variable-role-code" key="StructureDefinition-variable-definition-variable-role-code" name="VariableDefinitionVariableRoleCode"/>
<artifact id="StructureDefinition/web-page-citation" key="StructureDefinition-web-page-citation" name="WebPageCitation"/>
<artifact id="Citation/179561" key="Citation-179561" name="WebPageCitation: A HEvKA Update Summary"/>
<page key="NA" name="(NA)"/>
<page key="many" name="(many)"/>
<page key="artifactassessment" name="ArtifactAssessment Profiles"/>
<page key="artifacts" name="Artifacts Summary"/>
<page key="citation" name="Citation Profiles"/>
<page key="composition" name="Composition Profiles"/>
<page key="evidence" name="Evidence Profiles"/>
<page key="evidencevariable" name="EvidenceVariable Profiles"/>
<page key="examples" name="Examples"/>
<page key="extensions" name="Extensions"/>
<page key="group" name="Group Profiles"/>
<page key="index" name="Introduction"/>
<page key="otherprofiles" name="Other Profiles"/>
<page key="profiles" name="Profiles"/>
<page key="toc" name="Table of Contents"/>
<page key="terminologies" name="Terminologies"/>
</specification>